Follow‐up of offspring and mothers with gestational diabetes treated with metformin or glibenclamide: A randomized controlled trial

Paul, Praveen G.; Priyambada, Leena; Abraham, Anuja; Babuji, Manimegalai; Paul, Thomas; Princy, Sneha F X; Antonisamy, B.; Nicolaï, Thomas; Yenuberi, Hilda; Mathews, Jiji Elizabeth

doi:10.1002/ijgo.13380

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study also did not find any difference in terms of the likelihood of having a weight for height percentile greater than the 85 th percentile in the children of metformin-exposed mothers as compared to insulin treated counterparts. A recent study from India reported nine years of follow-up data of the offspring of mothers who were randomized either to metformin or glibenclamide during their GDM management[ 16 ]. They found no difference in BMI, WC or visceral fat distribution between the treatment groups.…”

Section: Long-term Effects Of Metformin On Offspring Of Mothers With Gestational Diabetesmentioning

confidence: 99%

Long-term effects of metformin use in gestational diabetes mellitus on offspring health

Roy¹,

Sahoo²

2021

WJD

View full text Add to dashboard Cite

Metformin is the first-line drug for the treatment of type 2 diabetes mellitus, but its role in gestational diabetes mellitus (GDM) management is not clear. Recent evidence suggests a certain beneficial effect of metformin in the treatment of GDM, but a high treatment failure rate leads to the initiation of additional medications, such as insulin. Moreover, since metformin crosses the placental barrier and reaches a significant level in the fetus, it is likely to influence the fetal metabolic milieu. The evidence indicates the long-term safety in children exposed to metformin in utero except for mild adverse anthropometric profiles. Diligent follow-up of metformin-exposed offspring is warranted from the clinician’s point of view.

show abstract

Section: Long-term Effects Of Metformin On Offspring Of Mothers With Gestational Diabetesmentioning

confidence: 99%

Long-term effects of metformin use in gestational diabetes mellitus on offspring health

Roy¹,

Sahoo²

2021

WJD

View full text Add to dashboard Cite

show abstract

The Study of Offspring and Mothers with Gestational Diabetes Treated with Metformin or Glibenclamide in a Randomized Controlled Trial after 9 Years

Tirkey

Paul

Kingsbury

et al. 2023

Current Medical Issues

View full text Add to dashboard Cite

Introduction: Follow-up of the mothers and their offspring recruited to a randomized controlled trial comparing neonatal outcomes in women with gestational diabetes treated with metformin or glibenclamide was conducted 9 years ago. A significant decrease in neonatal hypoglycemia in the group treated with metformin was seen in the original study. Methodology: Results of clinical examination, blood sample collection, and dual-energy X-ray absorptiometry (DEXA) scan not published in a brief communication are described in this study. The nutritional status was assessed using a 3-day recall method using the Indian Food Composition Table 2017. The physical activity of offspring was assessed using the Global Physical Activity Questionnaire. Results: The overall follow-up rate of the cohort was 49% and similar in both the groups. The anthropometric details, blood tests, and DEXA in the women and their offspring were similar except that the offspring of the group on metformin had higher triglyceride values than the offspring of the women treated with glibenclamide. The average body mass index of the offspring was similar and was 18. Currently, women who were treated with glibenclamide 9 years ago had higher fasting plasma glucose levels (9.2 [7.3, 12.6]) than the metformin group (7.2 [6.1, 8.4] median [interquartile range]), P = 0.02. They also had significantly higher diastolic blood pressure readings 77.1mmHg (8.9) and 72.1mmHg (11.7) mean (SD), P = 0.035. (Information from the previously published brief communication). Conclusion: No significant adverse outcome was seen in women treated with metformin and the offspring 9 years later.

show abstract

Follow‐up of offspring and mothers with gestational diabetes treated with metformin or glibenclamide: A randomized controlled trial

Abstract: Synopsis A 9‐year follow‐up of a randomized controlled trial showed metformin to have better neonatal outcomes than glibenclamide.

Cited by 2 publications

References 6 publications

Long-term effects of metformin use in gestational diabetes mellitus on offspring health

Long-term effects of metformin use in gestational diabetes mellitus on offspring health

The Study of Offspring and Mothers with Gestational Diabetes Treated with Metformin or Glibenclamide in a Randomized Controlled Trial after 9 Years

Contact Info

Product

Resources

About